Published DateClear

Start Date

End Date

Category

• Pipeline2

Organizations

• Bausch + Lomb72
• Eyes On Eyecare55
• Alcon, Inc.49
• American Optometric Association38
• Harrow32
• Glaukos30
• Topcon Healthcare26
• Regeneron25
• Aldeyra Therapeutics21
• Coopervision19

Tags

• Clinical Trials2
• Cornea2

• Organizations: Amber Ophthalmics✕

Clear all

Pipeline

Amber Ophthalmic enrolls first patient in PCED study

Phase 2/3 NEXPEDE-2 study is assessing two doses of Nexagon to target corneal healing.

Pipeline

Positive topline phase 2 data reported for PCED treatment

A total of 67% of subjects receiving NEXAGON achieved complete epithelial recovery.